In this article, a case of Crimean-Congo hemorrhagic fever (CCHF) and visceral leishmaniasis coinfection in a 14-month-old girl is reported. The case has been evaluated according to two different points of view based on the coexistence of CCHF and visceral leishmaniasis and a strongly suggested horizontal transmission of CCHF from her father. To the best of our knowledge, this coinfection has not been previously reported in literature.
Get full access to this article
View all access options for this article.
References
1.
AtharMN, BaqaiHZ, AhmadMet al.Short report: Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002. Am J Trop Med Hyg, 2003; 69:284–287.
2.
BakirM, UgurluM, DokuzoguzBet al.Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol, 2005; 54:385–389.
3.
BurtFJ, SwanepoelR, ShiehWJet al.Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med, 1997; 121:839–846.
4.
Centers for Disease Control Prevention. Crimean-Congo hemorrhagic fever republic of South Africa. MMWR Morb Mortal Wkly Rep, 1985; 34:99–101.
5.
CevikMA, ErbayA, BodurHet al.Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis, 2008; 12:374–379.
6.
ChiouHE, LiuCL, ButtreyMJ, KuoHPet al.Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest, 2005; 128:263–272.
7.
ErgönülO. Clinical and pathologic features of Crimean Congo hemorrhagic fever. ErgonulO, WhitehouseCA. Crimean-Congo Hemorrhagic Fever: A Global Perspective. Dordrecht (NL): Springer, 2007; 207–220.
8.
ErgonulO, CelikbasA, DokuzoguzBet al.Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis, 2004; 39:284–287.
9.
GozalanA, AkınL, RolainJMet al.Epidemiological evaluation of a possible outbreak in and nearby Tokat provinence. Mikrobiol Bull, 2004; 38:33–44.
10.
IzadiS, SalehiM, Holakouie-NaieniKet al.The risk of transmission of Crimean-Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J Infect Dis, 2008; 6:494–496.
11.
KnowlesSR, PhillipsEJ, DresserL, MatukasL. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis, 2003; 37:1139–1142.
OzkurtZ, KikiI, ErolSet al.Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect, 2006; 52:207–215.
14.
Turkey Ministry of Health. Primary Health Care Department: Infectious Disease and Outbreak Registration and Control Unit. 2005–2008 datasupdated2009.
15.
SaijoM, TangQ, ShimayiBet al.Possible horizontal transmission of crimean-congo hemorrhagic Fever virus from a mother to her child. Jpn J Infect Dis, 2004; 57:55–57.
TozSO, NasereddinA, OzbelYet al.Leishmaniasis in Turkey: molecular characterization of Leishmania from human and canine clinical samples. Trop Med Int Health, 2009; 14:1401–1406.
18.
WattsDM, UsseryMA, NashD, PetersJC. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg, 1989; 41:581–585.
19.
YilmazGR, BuzganT, IrmakHet al.The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002–2007. Int J Infect Dis, 2009; 13:380–386.
